$EOCN

Eocene Ltd. (NASDAQ: EOCN) announced its subsidiary Colospan Ltd. signed a European distribution agreement with Hospital Line SA for the CG-100 device in Greece and Cyprus. The agreement grants exclusive rights to market, sell, and distribute CG-100, with plans for a commercial launch. Colospan aims to expand into additional European markets. The device is intended to reduce the need for diverting stomas in colorectal surgery.

Galmed Pharmaceuticals rebrands to EoCene, changes ticker to EOCN. The company terminated its SEPA with Yorkville, raising $7.3M. EoCene focuses on GI diseases and cancers, integrating Colospan's medical device tech. It regained Nasdaq compliance and has $11.4M in cash. Changes take effect September 10, 2026.

Modular Medical (MODD) received FDA clearance for software enhancements to its Pivot insulin pump, planning a commercial launch in October 2026. Galmed (GLMD) shareholders approved all proposals, including a name change. Pro-Dex (PDEX) reported strong Q4 results with 17% sales growth. eHealth (EHTH) saw after-hours gains despite a Q2 net loss. Connect Biopharma (CNTB) will present at a conference and report Phase 2 trial results. AVITA Medical (RCEL) expects full-year revenue of $86M-$89M.

Galmed Pharmaceuticals' subsidiary Colospan completed a feasibility study for a novel intraoperative colon tissue quality assessment platform, enrolling 32 colorectal cancer patients. The study demonstrated technical feasibility, with successful measurements in all patients. This technology complements Colospan's CG-100 device and aligns with Galmed's strategy to diversify its portfolio in colorectal surgery. According to the company, the results support further development and potential future

Galmed Pharmaceuticals (GLMD) reported first preclinical results that its Aramchol SCD1 inhibitor plus enzalutamide (Xtandi) increased prostate cancer cell death 3-4x versus enzalutamide alone in VCaP cells. The effect grew with longer exposure, suggesting possible delay of resistance. GLMD stock was about $0.58, up 9.23%.

Galmed Pharmaceuticals (NASDAQ: GLMD) said Nasdaq granted an additional 180 days, extending the deadline to Jan. 25, 2027, to regain compliance with the $1 minimum bid price rule. Nasdaq initially notified GLMD on Jan. 29, 2026, and the prior deadline was July 28, 2026. Compliance requires a $1 or higher close for 10 straight trading days.

Galmed Pharmaceuticals (NASDAQ:GLMD) said its orally dispersible film formulation of Aramchol for Parkinson’s aims to improve drug delivery. The company reported about 150% higher systemic bioavailability and about 300% higher CNS exposure versus conventional oral dosing, with rapid dissolution and buccal/sublingual absorption, per its press release.

Galmed Pharmaceuticals announced a new brain-penetrant formulation of its drug Aramchol, co-developed with Barcode Nanotech. This new formulation, delivered via lipid nanoparticles, can cross the blood-brain barrier and is intended to treat synucleinopathies like Parkinson's disease. The development expands Aramchol's potential from liver diseases into high-unmet-need Central Nervous System indications, leveraging AI-enabled screening for optimal delivery.

Galmed Pharmaceuticals Ltd. (GLMD) has adjourned its Special General Meeting of Shareholders due to a lack of quorum. The meeting, originally scheduled for March 4, 2026, will now reconvene on March 5, 2026, at 4:00 p.m. Israel time at the offices of Meitar Law Offices. This information has been incorporated by reference into the company's existing Form S-8 and Form F-3 registration statements.

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 200 points on Monday. The Dow traded down 0.27% to 40,004.11 while the NASDAQ fell 1.19% to 17,175.43. The S&P 500 also fell, dropping, 0.72% to 5,485.36. Financial shares jumped by 0.6% on Monday.